Each year, drugs must be withdrawn from the market following the identification of serious adverse reactions. We report here on an enquiry addressed to persons involved in the recent withdrawal of nefazodone, and a survey of physicians and pharmacists. Our results show the complexities of such withdrawal decisions and the difficulty in communicating them through the network of health professionals down to the patients.